透明质酸在慢阻肺中的治疗潜力
本文综述慢阻肺治疗需求及透明质酸潜力。α1抗胰蛋白酶缺乏症发现引出蛋白酶-抗蛋白酶失衡假说,弹性蛋白交联氨基酸DI可作降解生物标志物。RAPID研究显示CT解剖指数与DI相关,提示保留弹性蛋白结构或延缓慢阻肺进展,透明质酸气雾剂在动物中减轻肺气肿、在初步人体研究中降低DI水平,值得进一步开发。
要点
- 弹性蛋白降解标志物DI与慢阻肺CT解剖指数相关。
- 透明质酸气雾剂在动物中减轻弹性蛋白酶诱导的肺气肿。
- 初步人体研究显示透明质酸气雾剂可降低DI水平。
核心结论
- 透明质酸作为慢阻肺治疗手段值得进一步开发。
研究设计与样本
- 本文为综述,基于慢阻肺临床病程、α1抗胰蛋白酶缺乏症相关假说及RAPID研究等证据进行论述。
主要发现
- RAPID研究显示慢阻肺CT影像解剖指数与基质损伤化学指标DI相关。
- 动物实验中透明质酸气雾剂减轻弹性蛋白酶诱导的肺气肿严重程度。
- 初步人体研究中透明质酸气雾剂诱导DI水平降低。
临床怎么用
- 提示保留肺弹性蛋白结构可能延缓慢阻肺进展,透明质酸是潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Insights into the clinical course of COPD indicate the need for new therapies for this condition. The discovery of alpha-1 antitrypsin deficiency (AATD) led to the protease-antiprotease imbalance hypothesis, which was applied to COPD related to AATD as well as COPD not related to AATD. The discovery of AATD brought recognition to the importance of elastin fibers in maintaining lung matrix structure. Two cross-linking amino acids, desmosine and isodesmosine (DI), are unique to mature elastin and can serve as biomarkers of the degradation of elastin. The intravenous augmentation treatment and lung density in severe alpha-1 antitrypsin deficiency (RAPID) study shows a correlation of an anatomic index of COPD (on CT imaging) correlating with a chemical indicator of matrix injury in COPD, DI. The results suggest that preservation of lung elastin structure may slow the progression of COPD. Hyaluronan aerosol decreases the severity of elastase-induced emphysema in animals and has induced reductions in DI levels in preliminary human studies. Hyaluronan deserves further development as a therapy for COPD.
引用
- Turino GM, Ma S, Lin YY, et al. The Therapeutic Potential of Hyaluronan in COPD. Chest. 2017. PMID: 29289686. doi:10.1016/j.chest.2017.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。